Opi
www.orphan-opi.com

From development to sales of pharmaceuticals for rare and severe diseases in haematology, oncology and neurology. Sales over 20m€. Products in phase II. Acquired by EUSA in March 2007 for 109m€

OPi, founded in 1999, is a European biopharmaceutical company whose mission is to develop and market pharmaceuticals aimed at treating patients suffering from rare and severe diseases. The Company has already one product approved in Europe and several products under clinical development. Innovation and medical needs are the mainstays of OPi’s approach. OPi was acquired by EUSA Pharma in March 2007 for 109m€